References
- Jaganathan SK, Vellayappan MV, Narasimhan G, et al. Chemopreventive effect of apple and berry fruits against colon cancer. WJG. 2014;20:17029–17036.
- Wang ZX, Cao JX, Liu ZP, et al. Combination of chemotherapy and immunotherapy for colon cancer in China: a meta-analysis. World J Gastroenterol. 2014;20:1095–1106.
- Voena C, Chiarle R. Advances in cancer immunology and cancer immunotherapy. Discov Med. 2016;21:125–133.
- Williams JA. Improving DNA vaccine performance through vector design. Curr Gene Ther. 2014;14:170–189.
- Li L, Petrovsky N. Molecular mechanisms for enhanced DNA vaccine immunogenicity. Expert Rev Vaccines. 2016;15:313–329.
- Xiao A, Zheng XJ, Song C, et al. Synthesis and immunological evaluation of MUC1 glycopeptide conjugates bearing N-acetyl modified STn derivatives as anticancer vaccines. Org Biomol Chem. 2016;14:7226–7237.
- Pillai K, Pourgholami MH, Chua TC, et al. MUC1 as a potential target in anticancer therapies. Am J Clin Oncol. 2015;38:108–118.
- Kreiter S, Diken M, Selmi A, et al. FLT3 ligand enhances the cancer therapeutic potency of naked RNA vaccines. Cancer Res. 2011;71:6132–6142.
- Kreiter S, Diken M, Selmi A, et al. FLT3 Ligand as a molecular adjuvant for naked RNA vaccines. Methods Mol Biol. 2016;1428:163–175.
- Kim NY, Chang DS, Kim Y, et al. Enhanced immune response to DNA vaccine encoding bacillus anthracis pa-d4 protects mice against anthrax spore challenge. PLoS One. 2015;10:e0139671.
- Perez-Shibayama C, Gil-Cruz C, Nussbacher M, et al. Dendritic cell-specific delivery of Flt3L by coronavirus vectors secures induction of therapeutic antitumor immunity. PLoS One. 2013;8:e81442.
- Xu Q, Zhu YF, Wang HC, et al. Enhanced efficacy of DNA vaccination against botulinum neurotoxin serotype A by co-administration of plasmids encoding DC-stimulating Flt3L and MIP-3α cytokines. Biologicals. 2016;44:441–447.
- Gao XY, Wang XL. An adoptive T cell immunotherapy targeting cancer stem cells in a colon cancer model. J Buon. 2015;20:1456–1463.
- Horm TM, Schroeder JA. MUC1 and metastatic cancer: expression, function and therapeutic targeting. Cell Adh Migr. 2013;7:187–198.
- Rabassa ME, Larrain MT, Lacunza E, et al. Nuclear localization of MUC1 extracellular domain in breast, head and neck, and colon cancer. Int J Biol Markers. 2015;30:e294–e300.
- Saeki N, Sakamoto H, Yoshida T. Mucin 1 gene (MUC1) and gastric-cancer susceptibility. Int J Mol Sci. 2014;15:7958–7973.
- Remy-Ziller C, Thioudellet C, Hortelano J, et al. Sequential administration of MVA-based vaccines and PD-1/PD-L1-blocking antibodies confers measurable benefits on tumor growth and survival: Preclinical studies with MVA-βGal and MVA-MUC1 (TG4010) in a murine tumor model. Hum Vaccin Immunother. 2017;19:1–6.